290 related articles for article (PubMed ID: 28646172)
21. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
22. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
23. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
24. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
[TBL] [Abstract][Full Text] [Related]
25. Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells.
Deng Y; Zhang J; Wang Z; Yan Z; Qiao M; Ye J; Wei Q; Wang J; Wang X; Zhao L; Lu S; Tang S; Mohammed MK; Liu H; Fan J; Zhang F; Zou Y; Liao J; Qi H; Haydon RC; Luu HH; He TC; Tang L
Sci Rep; 2015 Dec; 5():17523. PubMed ID: 26639992
[TBL] [Abstract][Full Text] [Related]
26. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
Necchi A; Lo Vullo S; Perrone F; Raggi D; Giannatempo P; Calareso G; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Togliardi E; Colecchia M; Busico A; Gloghini A; Testi A; Mariani L; Salvioni R
BJU Int; 2018 Mar; 121(3):348-356. PubMed ID: 28921872
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin Plus Cetuximab Inhibits Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Migration and Proliferation but Does Not Enhance Apoptosis.
Choi HS; Kim YK; Yun PY
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360933
[TBL] [Abstract][Full Text] [Related]
28. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.
Zahonero C; Aguilera P; Ramírez-Castillejo C; Pajares M; Bolós MV; Cantero D; Perez-Nuñez A; Hernández-Laín A; Sánchez-Gómez P; Sepúlveda JM
Mol Cancer Ther; 2015 Jul; 14(7):1548-58. PubMed ID: 25939761
[TBL] [Abstract][Full Text] [Related]
30. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells.
Lim YJ; Kim HS; Bae S; So KA; Kim TJ; Lee JH
Molecules; 2024 Jan; 29(1):. PubMed ID: 38202856
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth.
Rea K; Roggiani F; De Cecco L; Raspagliesi F; Carcangiu ML; Nair-Menon J; Bagnoli M; Bortolomai I; Mezzanzanica D; Canevari S; Kourtidis A; Anastasiadis PZ; Tomassetti A
J Exp Clin Cancer Res; 2018 Jul; 37(1):146. PubMed ID: 29996940
[TBL] [Abstract][Full Text] [Related]
32. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
Engels K; Knauer SK; Loibl S; Fetz V; Harter P; Schweitzer A; Fisseler-Eckhoff A; Kommoss F; Hanker L; Nekljudova V; Hermanns I; Kleinert H; Mann W; du Bois A; Stauber RH
Cancer Res; 2008 Jul; 68(13):5159-66. PubMed ID: 18593915
[TBL] [Abstract][Full Text] [Related]
33. Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
Williams JP; Kim I; Ito E; Shi W; Yue S; Siu LL; Waldron J; O'Sullivan B; Yip KW; Liu FF
PLoS One; 2014; 9(5):e98557. PubMed ID: 24853121
[TBL] [Abstract][Full Text] [Related]
34. PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.
Hou L; Hou X; Wang L; Li Z; Xin B; Chen J; Gao X; Mu H
Cancer Biomark; 2017 Dec; 21(1):187-194. PubMed ID: 29103028
[TBL] [Abstract][Full Text] [Related]
35. Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.
Wang X; Goldstein D; Crowe PJ; Yang JL
Int J Oncol; 2018 Jun; 52(6):2143-2154. PubMed ID: 29620166
[TBL] [Abstract][Full Text] [Related]
36. IGF1R-α6 integrin-S100A4 network governs the organ-specific metastasis of chemoresistant epithelial ovarian cancer cells.
Deo AN; Thorat R; Dhadve AC; De A; Rekhi B; Ray P
Biochim Biophys Acta Mol Basis Dis; 2022 Jan; 1868(1):166282. PubMed ID: 34600083
[TBL] [Abstract][Full Text] [Related]
37. Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM.
Yang Z; Liu Y; Wei X; Zhou X; Gong C; Zhang T; Jin P; Xu S; Ma D; Gao Q
Curr Cancer Drug Targets; 2015; 15(3):215-26. PubMed ID: 25619386
[TBL] [Abstract][Full Text] [Related]
38. Smad7 maintains epithelial phenotype of ovarian cancer stem-like cells and supports tumor colonization by mesenchymal-epithelial transition.
Li Y; Gong W; Ma X; Sun X; Jiang H; Chen T
Mol Med Rep; 2015 Jan; 11(1):309-16. PubMed ID: 25333457
[TBL] [Abstract][Full Text] [Related]
39. Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.
Francis DM; Huang S; Armstrong EA; Werner LR; Hullett C; Li C; Morris ZS; Swick AD; Kragh M; Lantto J; Kimple RJ; Harari PM
Clin Cancer Res; 2016 Feb; 22(3):633-43. PubMed ID: 26420857
[TBL] [Abstract][Full Text] [Related]
40. A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.
Endersby R; Whitehouse J; Hii H; Greenall SA; Johns TG; Gottardo NG
Neoplasia; 2018 May; 20(5):432-442. PubMed ID: 29574250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
